-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

487 Circulating Tumor Cells As a Biomarker to Identify High-Risk Transplant Eligible Myeloma Patients Treated with Bortezomib, Lenalidomide and Dexamethasone with or without Daratumumab during Induction/Consolidation, and Lenalidomide with or without Daratumumab during Maintenance: Results from the Perseus Study

Program: Oral and Poster Abstracts
Type: Oral
Session: 653. Multiple Myeloma: Clinical and Epidemiological: Cellular and Molecular Profiling of Multiple Myeloma: Implications for Clinical Practice
Hematology Disease Topics & Pathways:
Research, Clinical trials, Translational Research, Clinical Research, Plasma Cell Disorders, Diseases, Lymphoid Malignancies
Sunday, December 8, 2024: 9:30 AM

Luca Bertamini, MD1*, Cathelijne Fokkema, MD1*, Paula Rodríguez-Otero, MD, PhD2*, Mark van Duin, PhD1*, Niels W.C.J. Van De Donk, MD3, Mattia D'Agostino, MD4*, Evangelos Terpos, MD, PhD5, Diego Vieyra, PhD6*, Ricardo M. Attar, PhD6*, Anna Sitthi-Amorn7*, Robin Carson, MD7, Michel Delforge8*, Christoph Driessen9, Roman Hajek, MD, PhD10, Mario Boccadoro, MD11, Hermann Einsele, MD12, Annette Vangsted13*, Vincent H.J. Van Der Velden, PhD14*, Fredrik Schjesvold, MD, PhD15, Artur Jurczyszyn16*, Meral Beksac, MD17,18, Andrew Spencer, MBBS19*, Annemiek Broijl, PhD20, Tom Cupedo, PhD1*, Philippe Moreau, MD, PhD21* and Pieter Sonneveld, MD1

1Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
2Clinica Universidad de Navarra, Madrid, Spain
3Cancer Center Amsterdam, VU University Medical Center, Amsterdam, Netherlands
4Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
5Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Drosia, Attiki, Greece
6Janssen Research & Development, Spring House, PA
7Janssen Research & Development, LLC, Spring House, PA
8Universitair Ziekenhuis (UZ) Leuven, Leuven, Belgium
9Cantonal Hospital St. Gallen, St. Gallen, Switzerland
10University Hospital Ostrava and University of Ostrava, Ostrava, Czech Republic
11European Myeloma Network, EMN, Italy
12Division of Hematology, University Hospital of Wurzburg, Wurzburg, Germany, Würzburg, DEU
13Rigshospitalet, Copenhagen, Denmark
14Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
15Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway
16Jagiellonian University Medical College, Kraków, Poland
17Department of Hematology, Ankara University Faculty of Medicine, Department of Hematology, Ankara, Turkey
18Ankara Liv Hospital, Istinye University, Ankara, Turkey
19Alfred Health-Monash University, Melbourne, VIC, Australia
20Erasmus MC Cancer Institute, Rotterdam, Netherlands
21University Hospital Hôtel-Dieu, Nantes, France

Background

Circulating tumor cells (CTC) are increasingly being recognized as a prognostic biomarker for risk stratification in newly diagnosed multiple myeloma (NDMM). High percentage of CTC have been associated with inferior minimal residual disease (MRD) negativity-rate and progression free survival (PFS) in 2 recent trials (Bertamini et al, JCO 2022; Garces et al, JCO 2022). However, the prognostic value of CTC in patients receiving quadruplet (anti CD38, proteasome inhibitors, immunomodulatory drugs, steroids), autologous transplant, and maintenance which represents a new standard of care in transplant eligible (TE) NDMM, has not been investigated.

Methods

Peripheral blood samples of NDMM enrolled in the multicenter phase III PERSEUS randomized trial (NCT03710603; Sonneveld et al, NEJM 2023) were centrally analyzed at Erasmus MC. CTC were phenotyped and enumerated by flow cytometry (EuroFlow) with a median sensitivity of 4e-06 (range 2e-06- 1.3e-04). MRD in bone marrow at 10-5 and 10-6 was measured by next-generation sequencing (clonoSEQ®). Overall MRD negativity (MRD-neg) rate was defined as the proportion of participants in the ITT population who achieved both MRD negativity and a CR or better. Sustained MRD-neg was defined as 2 consecutive MRD-negative results at least 12 months apart with no MRD-positive results in between. High risk cytogenetic abnormalities (HRCA) were defined as the presence of del17p, t(4;14) and/or t(14;16) by FISH.

Cox multivariate (MV) proportional hazards regressions were performed for PFS including CTC as continuous variable (log10) or categorical (Low vs High), ISS (I vs II / III), cytogenetics (HRCA no vs yes/unknown), LDH (lower vs higher of upper limit of normality), and therapy (without vs with daratumumab). The optimal CTC cutoff was established using Cox regressions for PFS adjusted for ISS, LDH, and HRCA, identifying the cutoff with the highest C-index (Bertamini et al, JCO 2022). Medians were compared with Kruskal Wallis test, frequencies with chi-square test.

Results

Out of 709 patients enrolled in the PERSEUS study, 451 were tested for CTC, based on sample availability. The median follow-up was 48 months. Before start of therapy, CTCs were detected in 396 patients (87%). Median CTC values were similar in both arms (D-VRd 0.010%, 95%CI 0.0009-0.074%; VRd 0.0088%, 95%CI 0.0012-0.075%; p=0.8). As a continuous variable, higher CTC were strongly correlated to worse PFS (HR 1.36, 95% CI 1.15-1.6, p=4.07e-04) independent of HRCA, LDH, ISS, and treatment arm. This translated in reduced 4-year PFS estimates with patients categorized by increasing log10 CTC levels (CTC <=0.001%: 93%, CTC 0.001-0.01%: 79%; CTC 0.01-0.1%: 71%; CTC 0.1-1%: 67%; CTC>1%: 48%; log-rank p<0.0001).

Previously reported CTC cut-offs (e.g. 0.01%, 0.07%) identified patients with reduced PFS in PERSEUS, testifying to the robustness of the biomarker. For further analyses an optimal cut-off of 0.175% was calculated for this dataset, identifying 15.3% of patients with CTC above the threshold (CTC-High, n=69/451). As already reported, MRD-neg rates were higher in patients treated with D-VRd vs VRd (Sonneveld, EHA 2024), and this was true also for CTC-High and CTC-Low (≤0.175%) patients. Overall MRD-neg rates in CTC-high patients were: 69% D-VRd vs 34% VRd (p=0.008, 10-5 threshold) and 47% D-VRd vs 22% VRd (p=0.054, 10-6 threshold).Sustained MRD-neg rates in CTC-High patients were: 50% D-VRd vs 16% VRd (p=0.004, 10-5 threshold) and 39% D-VRd vs 6% VRd (p=0.003, 10-6 threshold).

In terms of PFS, D-VRd was superior to VRd in both CTC-High (4-year PFS rates D-VRd 58% vs VRd 40%) and CTC-Low patients (4-year PFS rates D-VRd 88% vs VRd 74%, log-rank p<0.001). Finally, a small group of 34 ultra high-risk patients was identified by combining both CTC-High and HRCA (4 year-PFS: CTC-High HRCA 29% vs CTC-High Standard risk CA 73% vs CTC-Low HRCA 68% vs CTC-Low Standard risk CA 84%, log-rank p<0.001). However, analysis by treatment arm was not possible due to small numbers.

Conclusions

CTC is an independent prognostic factor in the context of the most effective standard of care for TE NDMM. The presence of both high CTC and HRCA identifies a group of patients with an overall dismal outcome. The addition of daratumumab to VRd induction/consolidation and R maintenance improves outcome in NDMM patients with high-risk disease defined by high CTC, leading to higher rates of deep and sustained MRD-neg and better PFS.

Disclosures: Rodríguez-Otero: AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Other: Honoraria for lectures; Sanofi: Membership on an entity's Board of Directors or advisory committees, Other: Honoraria for lectures; Roche: Consultancy; Oncopeptides: Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Honoraria for lectures; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Travel grants; Johnson & Johnson - Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Honoraria for lectures; Regeneron: Other: Honoraria for lectures; GSK: Membership on an entity's Board of Directors or advisory committees, Other: Honoraria for lectures; Takeda: Membership on an entity's Board of Directors or advisory committees, Other: Honoraria for lectures; Kite Pharma: Membership on an entity's Board of Directors or advisory committees. D'Agostino: GlaxoSmithKline: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Research Funding; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Adaptive Biotechnologies: Membership on an entity's Board of Directors or advisory committees. Terpos: Amgen: Honoraria, Other: Travel expenses, Research Funding; EUSA Pharma: Honoraria, Other: Travel expenses; Menarini/Stemline: Honoraria; BMS: Honoraria; GSK: Honoraria, Research Funding; AstraZeneca: Honoraria, Other: Travel expenses; Janssen: Honoraria, Research Funding; Pfizer: Honoraria; Sanofi: Honoraria, Other: Travel expenses, Research Funding; Takeda: Honoraria, Other: Travel expenses, Research Funding; Novartis: Honoraria; Antengene: Honoraria, Research Funding; Swixx: Honoraria. Vieyra: Janssen Research & Development, LLC: Current Employment, Current equity holder in publicly-traded company. Attar: Johnson & Johnson: Current Employment, Current holder of stock options in a privately-held company. Sitthi-Amorn: Janssen: Current Employment, Current equity holder in publicly-traded company. Carson: Janssen: Current Employment, Current holder of stock options in a privately-held company. Delforge: Amgen, BMS, GSJ, Janssen, Sanofi, Pfizer, Roche: Honoraria; Amgen, BMS, GSJ, Janssen, Sanofi, Pfizer, F. Hoffmann-La Roche Ltd: Consultancy; Janssen: Consultancy, Honoraria; BMS: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; GSK: Consultancy, Honoraria; Roche: Consultancy, Honoraria; University Hospital Leuven: Consultancy, Honoraria. Hajek: Takeda: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Research Funding; AbbVie: Consultancy; BMS: Consultancy, Honoraria, Research Funding; PharmaMar: Consultancy, Honoraria; Novartis: Consultancy, Research Funding. Boccadoro: Celgene: Honoraria, Research Funding; Amgen: Honoraria, Research Funding; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Honoraria, Research Funding; Bristol Myers Squibb: Honoraria, Research Funding; AbbVie: Honoraria; GlaxoSmithKline: Membership on an entity's Board of Directors or advisory committees; Mundipharma: Research Funding; Sanofi: Honoraria, Research Funding. Einsele: Celgene/Bristol-Meyers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS: Honoraria; Sanofi: Honoraria; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees. Van Der Velden: BD Biosciences: Other: Laboratory Services Agreement; Agilent: Other: Laboratory Services Agreement. Schjesvold: Daiichi Sankyo: Other: Honoraria for lectures and educational material; Targovax: Research Funding; Amgen: Other: Honoraria for lectures and educational material; Bristol Myers Squibb: Consultancy, Other: Honoraria for lectures and educational material; Novartis: Other: Honoraria for lectures and educational material; SkylineDx: Other: Honoraria for lectures and educational material; Takeda: Consultancy, Other: Honoraria for lectures and educational material; GSK: Consultancy, Honoraria, Research Funding; AbbVie: Consultancy, Other: Honoraria for lectures and educational material; GlaxoSmithKline: Consultancy, Honoraria, Research Funding; Janssen-Cilag: Consultancy, Other: Honoraria for lectures and educational material, Research Funding; Sanofi: Consultancy, Other: Honoraria for lectures and educational material, Research Funding; Pfizer: Other: Honoraria for lectures and educational material; Schain: Other: Honoraria for lectures and educational material; Skylite: Other: Honoraria for lectures and educational material; Celgene: Consultancy, Other: Honoraria for lectures and educational material, Research Funding; Oncopeptides: Consultancy, Other: Honoraria for lectures and educational material, Research Funding. Beksac: Janssen: Research Funding, Speakers Bureau; Menarini: Consultancy, Other: advisory; GSK: Research Funding; Sanofi: Speakers Bureau; Bristol Myers Squibb: Speakers Bureau; Amgen: Speakers Bureau; Takeda: Membership on an entity's Board of Directors or advisory committees. Spencer: F. Hoffmann-La Roche Ltd: Honoraria, Membership on an entity's Board of Directors or advisory committees; AbbVie: Honoraria, Research Funding. Broijl: BMS: Honoraria, Speakers Bureau; Sanofi: Honoraria, Speakers Bureau; Johnson & Johnson: Honoraria, Speakers Bureau. Cupedo: Janssen: Research Funding. Moreau: AbbVie, Amgen, Celgene, Janssen, Oncopeptides, Roche, Sanofi: Consultancy, Honoraria. Sonneveld: Janssen: Membership on an entity's Board of Directors or advisory committees, Patents & Royalties, Research Funding; Karyopharm: Membership on an entity's Board of Directors or advisory committees, Patents & Royalties, Research Funding; European Myeloma Network: Other: President; Oncopeptides: Patents & Royalties; Pfizer: Membership on an entity's Board of Directors or advisory committees, Patents & Royalties; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Membership on an entity's Board of Directors or advisory committees, Research Funding.

Previous Abstract | Next Abstract >>
*signifies non-member of ASH